Radiation and Immunotherapy for Pancreatic Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if adding radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with pancreatic cancer that has come back or spread. It is for those who haven't had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic cancer that has spread or come back and cannot be surgically removed.
- You must not have had any prior chemotherapy or radiation for advanced disease, or if you had treatment after surgery, it was more than 6 months ago.
- You must be between 18 and 75 years old.
- You must have at least one tumor that can be measured on a scan and is suitable for radiation.
- You must have a maximum of 10 metastases (spread areas) outside the primary tumor, with the largest no bigger than 10 cm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving targeted radiation (SBRT) followed by an experimental immunotherapy drug injected directly into the tumor is safe for people with locally advanced pancreatic cancer. It aims to shrink the tumor and help your immune system fight it.
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests a very focused type of radiation (SBRT) for people with pancreatic cancer that hasn't spread to other organs but can't be removed with surgery. It may be an option if you are medically unable to have surgery or choose not to.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests whether adding a focused radiation treatment (SBRT) to ongoing chemotherapy drugs works better than the drugs alone for pancreatic cancer that has stabilized or shrunk after initial treatment. The goal is to see if this combination approach helps patients live longer.
Hear when a new PDAC - Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.